Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
prednisone and prednisolone derivatives	4548	2135-17-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: flumetasone flucorticin flumethason fluorodexamethazone flumethasone	An anti-inflammatory glucocorticoid used in veterinary practice. Molecular weight: 410.46 Formula: C22H28F2O5 CLOGP: 1.83 LIPINSKI: 0 HAC: 5 HDO: 3 TPSA: 94.83 ALOGS: -3.68 ROTB: 2 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

flumetasone
flucorticin
flumethason
fluorodexamethazone
flumethasone

An anti-inflammatory glucocorticoid used in veterinary practice.

Molecular weight: 410.46
Formula: C22H28F2O5
CLOGP: 1.83
LIPINSKI: 0
HAC: 5
HDO: 3
TPSA: 94.83
ALOGS: -3.68
ROTB: 2

Status: OFM

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	1.942		High	0.86
caco2-efflux	Caco-2 efflux ratio (BA/AB)	4.036		High	0.86
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	25.527	10^-6 cm/s	High	0.86
dh-clint	Dog hepatocyte intrinsic clearance	5.689	uL/min/10^6 cells	High	0.86
dppb	Dog plasma protein binding (% unbound)	37.820	%	High	0.86
fcs-ppb	Fetal calf serum protein binding (% unbound)	46.320	%	High	0.86
herg	hERG pIC50	4.396	pIC50	High	0.86
hh-clint	Human hepatocyte intrinsic clearance	2.099	uL/min/10^6 cells	High	0.86
hlm-clint	Human liver microsomal intrinsic clearance	9.290	uL/min/mg protein	High	0.86
hppb	Human plasma protein binding (% unbound)	25.310	%	High	0.86
kinase-safety-class	ACVR2B,CDK5,EIF2AK3,GRK2,ITK,MAPK10,PDK1,PDK2,PDK4,PRKDC	10
kinase-selectivity-class	GRK2,MAP2K6,PDK1	3
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	13.305		Moderate	0.71
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	8.590		High	0.86
mh-clint	Mouse hepatocyte intrinsic clearance	16.106		High	0.86
mppb	Mouse plasma protein binding (% unbound)	36.050		High	0.86
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	17.219		High	0.86
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pld-class	Phospholipidosis risk class (1 = positive, 0 = negative)	0		Moderate	0.71
pppb	Pig plasma protein binding (% unbound)	37.760	%	High	0.86
rat-kpuu-brain	Rat brain Kpuu	0.070	%	Moderate	0.71
rh-clint	Rat hepatocyte intrinsic clearance	24.434	uL/min/10^6 cells	High	0.86
rh-fuinc	Rat hepatocyte fraction unbound in incubation	75.930	%	High	0.86
rppb	Rat plasma protein binding (% unbound)	24.920	%	High	0.86
solubility-dd	Solubility at pH 7.4 in DMSO	417.830	uM	High	0.86

Approvals:

Date	Agency	Company	Orphan
None	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product label confusion	406.08	98.54	189	33547	22661	90572050
Blepharospasm	355.50	98.54	234	33502	55211	90539500
Grip strength decreased	350.39	98.54	284	33452	92292	90502419
Finger deformity	335.45	98.54	187	33549	32710	90562001
Coeliac disease	329.87	98.54	206	33530	44404	90550307
Adverse reaction	325.26	98.54	177	33559	29535	90565176
Back injury	324.01	98.54	207	33529	46415	90548296
Nail disorder	323.20	98.54	226	33510	58841	90535870
Breast cancer stage III	308.88	98.54	254	33482	84193	90510518
Epilepsy	285.56	98.54	240	33496	81966	90512745
Taste disorder	267.65	98.54	205	33531	61341	90533370
Bursitis	266.58	98.54	285	33451	131369	90463342
Facet joint syndrome	263.64	98.54	248	33488	98141	90496570
Onychomycosis	247.46	98.54	161	33575	37215	90557496
Onychomadesis	246.94	98.54	174	33562	45824	90548887
Injury	238.70	98.54	329	33407	197020	90397691
Drug-induced liver injury	236.88	98.54	225	33511	90093	90504618
Dyspepsia	230.18	98.54	324	33412	197836	90396875
Hypercholesterolaemia	228.57	98.54	232	33504	100660	90494051
Hepatitis	222.19	98.54	195	33541	70544	90524167
Peripheral venous disease	218.04	98.54	208	33528	83713	90510998
Liver injury	217.81	98.54	292	33444	170275	90424436
Live birth	214.95	98.54	201	33535	78906	90515805
Gastrooesophageal reflux disease	205.14	98.54	280	33456	166057	90428654
Mobility decreased	204.27	98.54	348	33388	250386	90344325
Blood cholesterol increased	203.87	98.54	314	33422	207698	90387013
Product quality issue	203.03	98.54	195	33541	79130	90515581
Liver function test increased	199.28	98.54	199	33537	84656	90510055
Wound infection	197.31	98.54	220	33516	106182	90488529
Lip dry	194.55	98.54	213	33523	100742	90493969
Folliculitis	187.08	98.54	299	33437	204054	90390657
Migraine	178.99	98.54	282	33454	190110	90404601
Inflammation	174.10	98.54	269	33467	178323	90416388
Abdominal distension	173.45	98.54	228	33508	130373	90464338
Neck pain	157.61	98.54	203	33533	113760	90480951
Joint range of motion decreased	153.24	98.54	219	33517	135424	90459287
Obesity	150.72	98.54	191	33545	105316	90489395
Gait inability	143.25	98.54	221	33515	146235	90448476
Helicobacter infection	132.31	98.54	273	33463	226577	90368134
Type 2 diabetes mellitus	130.98	98.54	255	33481	202989	90391722
Hand deformity	129.62	98.54	318	33418	296044	90298667
Dry mouth	128.56	98.54	239	33497	183820	90410891
Psoriatic arthropathy	126.42	98.54	269	33467	228066	90366645
Duodenal ulcer perforation	122.85	98.54	261	33475	221027	90373684
Fibromyalgia	122.35	98.54	250	33486	206019	90388692
Injection site reaction	121.03	98.54	160	33576	91920	90502791
Anti-cyclic citrullinated peptide antibody positive	118.92	98.54	268	33468	236165	90358546
C-reactive protein increased	114.92	98.54	226	33510	181163	90413548
Ulcer haemorrhage	112.87	98.54	87	33649	26234	90568477
Glossodynia	107.99	98.54	313	33423	321466	90273245
Drug ineffective	107.65	98.54	222	33514	1384076	89210635
Hypoaesthesia	106.75	98.54	307	33429	313903	90280808
Pericarditis	106.74	98.54	279	33457	269872	90324839
Pruritus	103.97	98.54	36	33700	541489	90053222
Pemphigus	100.25	98.54	308	33428	326556	90268155
Sleep disorder	100.13	98.54	225	33511	197805	90396906
Night sweats	99.80	98.54	175	33561	128591	90466120
Intentional product use issue	99.32	98.54	237	33499	216655	90378056

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product label confusion	456.41	154.34	190	31841	22487	110534781
Grip strength decreased	451.39	154.34	284	31747	79890	110477378
Blepharospasm	390.62	154.34	226	31805	54625	110502643
Coeliac disease	387.00	154.34	207	31824	42980	110514288
Finger deformity	381.62	154.34	188	31843	32904	110524364
Adverse reaction	370.95	154.34	178	31853	29416	110527852
Breast cancer stage III	368.74	154.34	249	31782	78868	110478400
Nail disorder	363.58	154.34	220	31811	57715	110499553
Back injury	355.42	154.34	202	31829	47197	110510071
Bursitis	322.53	154.34	281	31750	129637	110427631
Facet joint syndrome	308.30	154.34	242	31789	96586	110460682
Hypercholesterolaemia	295.63	154.34	230	31801	90607	110466661
Taste disorder	283.81	154.34	197	31834	65190	110492078
Blood cholesterol increased	283.79	154.34	307	31724	184478	110372790
Folliculitis	283.13	154.34	293	31738	167360	110389908
Onychomycosis	282.91	154.34	162	31869	38369	110518899
Epilepsy	281.99	154.34	233	31798	99976	110457292
Onychomadesis	270.08	154.34	167	31864	45496	110511772
Hand deformity	258.05	154.34	317	31714	218189	110339079
Wound infection	254.26	154.34	216	31815	96249	110461019
Injury	247.12	154.34	280	31751	176985	110380283
Glossodynia	244.46	154.34	311	31720	221693	110335575
Product quality issue	243.43	154.34	192	31839	77107	110480161
Gastrooesophageal reflux disease	241.96	154.34	279	31752	179697	110377571
Live birth	241.51	154.34	183	31848	69301	110487967
Liver injury	236.31	154.34	253	31778	150160	110407108
Dyspepsia	235.11	154.34	283	31748	190682	110366586
Drug-induced liver injury	232.33	154.34	226	31805	119841	110437427
Peripheral venous disease	227.10	154.34	191	31840	83926	110473342
Mobility decreased	226.49	154.34	310	31721	237112	110320156
Helicobacter infection	226.30	154.34	271	31760	181606	110375662
Hepatitis	225.83	154.34	196	31835	89858	110467410
Liver function test increased	216.56	154.34	190	31841	88358	110468910
Anti-cyclic citrullinated peptide antibody positive	211.53	154.34	262	31769	181722	110375546
Lip dry	208.03	154.34	196	31835	99887	110457381
Duodenal ulcer perforation	205.19	154.34	255	31776	177445	110379823
Fibromyalgia	193.71	154.34	243	31788	170666	110386602
Migraine	192.87	154.34	243	31788	171409	110385859
Gait inability	189.27	154.34	215	31816	136161	110421107
Joint range of motion decreased	184.41	154.34	201	31830	121631	110435637
Inflammation	182.23	154.34	251	31780	192987	110364281
Pemphigus	176.30	154.34	261	31770	214309	110342959
Neck pain	175.76	154.34	197	31834	122933	110434335
Obesity	175.03	154.34	189	31842	113162	110444106
Type 2 diabetes mellitus	174.35	154.34	235	31796	176997	110380271
Arthropathy	171.08	154.34	302	31729	287220	110270048
Psoriatic arthropathy	169.85	154.34	245	31786	196516	110360752
Abdominal distension	167.42	154.34	229	31802	174874	110382394
Acute kidney injury	165.24	154.34	4	32027	635426	109921842
Pericarditis	162.30	154.34	254	31777	218860	110338408
Injection site reaction	158.06	154.34	160	31871	88910	110468358

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D07AB03	DERMATOLOGICALS CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS CORTICOSTEROIDS, PLAIN Corticosteroids, moderately potent (group II)
ATC	D07BB01	DERMATOLOGICALS CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS Corticosteroids, moderately potent, combinations with antiseptics
ATC	D07CB05	DERMATOLOGICALS CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS Corticosteroids, moderately potent, combinations with antibiotics
ATC	D07XB01	DERMATOLOGICALS CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS CORTICOSTEROIDS, OTHER COMBINATIONS Corticosteroids, moderately potent, other combinations
ATC	S02CA02	SENSORY ORGANS OTOLOGICALS CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION Corticosteroids and antiinfectives in combination
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D005938	Glucocorticoids
MeSH PA	D006728	Hormones
CHEBI has role	CHEBI:35472	anti-inflammatory drug

Related Drugs by ATC class:

D07AB Corticosteroids, moderately potent (group II) 12 drugs

alclometasone dipropionate clobetasone butyrate clocortolone pivalate desonide dexamethasone fluocortin butyl fluorometholone fluperolone fluprednidene hydrocortisone butyrate hydrocortisone probutate triamcinolone

D07BB Corticosteroids, moderately potent, combinations with antiseptics 3 drugs

desonide hydrocortisone butyrate triamcinolone

D07CB Corticosteroids, moderately potent, combinations with antibiotics 4 drugs

dexamethasone fluorometholone fluprednidene triamcinolone

D07XB Corticosteroids, moderately potent, other combinations 4 drugs

dexamethasone fluorometholone fluprednidene triamcinolone

S02CA Corticosteroids and antiinfectives in combination 6 drugs

dexamethasone fludrocortisone acetate fluocinolone acetonide hydrocortisone prednisolone triamcinolone

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Atopic dermatitis	indication	24079001	DOID:3310
Contact dermatitis	indication	40275004	DOID:2773
Seborrheic dermatitis	indication	50563003	DOID:8741
Lichen simplex chronicus	indication	53891004
Granuloma annulare	indication	65508009	DOID:3777
Pruritus ani	indication	90446007
Discoid lupus erythematosus	indication	200938002
Plaque psoriasis	indication	200965009
Scalp psoriasis	indication	238608008
Pruritus of genital organs	indication	267802000
Eruption of skin	indication	271807003	DOID:0050486
Primary cutaneous T-cell lymphoma	indication	400122007
Hypopituitarism	contraindication	74728003	DOID:9406
Skin striae	contraindication	201066002
Telangiectasia disorder	contraindication	247479008
Atrophoderma	contraindication	399979006

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Acute and chronic dermatoses of varying etiology	Indication
Dogs	Musculoskeletal conditions caused by inflammation of muscles or joints and accessory structures where permanent structural changes do not exist	Indication
Dogs	Acute and chronic dermatoses of varying etiology	Indication
Dogs	Otitis externa in conjunction with topical medication	Indication
Dogs	Allergic states	Indication
Dogs	Shock and shock-like states	Indication
Horse	Musculoskeletal conditions caused by inflammation, where permanent structural changes do not exist	Indication
Horse	Allergic states	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Flucort Solution	Zoetis Inc.	1
Flucort Tablets	Zoetis Inc.	1
Anaprime Suspension	Zoetis Inc.	1
Anaprime Ophthalmic Solution	Zoetis Inc.	3
Anaprime Opthakote Ophthalmic	Zoetis Inc.	3

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.06	acidic
pKa2	12.45	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D04208	KEGG_DRUG
N0000167461	NUI
CHEBI:34764	CHEBI
CHEMBL1201392	ChEMBL_ID
DB00663	DRUGBANK_ID
4458	RXNORM
004949	NDDF
116598007	SNOMEDCT_US
3037004	SNOMEDCT_US
C0016294	UMLSCUI
D005443	MESH_DESCRIPTOR_UI
16490	PUBCHEM_CID
1355	INN_ID
LR3CD8SX89	UNII
LR3CD8SX89	INXIGHT DRUGS

Pharmaceutical products:

None

Ask DrugCentral

flumetasone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: